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Abstract
In Japan, there are unique facilities (namely Ningen Dock) for health check-up that pro-
vide asymptomatic participants with a health examination, including cancer screening 
activities, at their own expense. The most advanced examination equipment and exami-
nations do not only provide high accuracy, but they also reduce stress on the body of the 
client. Usage of the medical equipment and diagnostic techniques allows us for success-
ful detection of many diseases in their early stages of development. This early detection 
leads to quicker response for the disease. On the other hand, gynecological cancer screen-
ing is a relatively simple, low cost, and noninvasive method. In this chapter, we introduce 
a major role of Ningen Dock in gynecological malignancy prophylaxis. Ningen Dock 
attendances are associated with extremely low positive gynecology cancer screening inci-
dence (0.03%). The level of knowledge and attitude toward screening may be related to 
multiple factors such as ethnicity, place of residence, income, and social-economic status. 
Not paying attention to cancer screening may be the risk factors for non-attendance to 
health check-up. These findings are of importance for improving the gynecological can-
cer screening practices of the lower screening attendance in Japan.
Keywords: health check-up, Ningen Dock, gynecological cancer, attitude toward 
screening, cancer screening, cervical cancer
1. Introduction
Health and medical check-ups aim to discover problems that may be harmful to the future 
health of the examinees, providing proposals for health promotion support solutions. Health 
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check-ups focus on comprehensive assessments regarding the whole body even without dis-
orders, while medical examinations include a specific disease or organ. In many countries, 
including Japan, a series of systemic routine health examinations and preventive medicine 
development in response to client needs undergo on a voluntary basis.
In Japan, there are unique facilities (namely Ningen Dock) for health check-up that provide asymp-
tomatic participants with a health examination, including cancer screening activities, at their own 
expense [1]. Japan is indeed a country in the world with the most advanced medical devices. For 
example, about half of the CT scans and about one-third of the MRI scans are owned by medical 
facilities in Japan [2]. The most advanced examination equipment and examinations do not only 
provide high accuracy, but they also reduce stress on the body of the client. Usage of the medical 
equipment and diagnostic techniques allows us for successful detection of many diseases in their 
early stages of development. This early detection leads to quicker response for the disease.
The “OMOTENASHI” services provided by staffs, including nurses, technologists, and 
doctors, is supporting the popularity. With the careful client support underpinned by the 
Japanese culture of hospitality, the Ningen Dock in Japan is popular in neighboring countries. 
The number of people from another country is rapidly increasing, to visit Japan, to receive the 
medical services of Ningen Dock. These situations prompted us to introduce a major role of 
Ningen Dock in gynecological malignancy prophylaxis.
2. Gynecological examination flow
In general, there are three Ningen Dock programs, a half-day course, one-day course, and 
two-day course. Depending on the selection of the course, different diagnostic and procedural 
options are available. The cost is not covered by the social insurance. Asymptomatic women, 
aged from 18 until ~90 undergo medical evaluations, including a medical history, physical 
examination, blood sampling, urine sampling, and radiological imaging, as part of a routine 
health check-up and cancer screening (see Table 1). The popular plan for women is a gyne-
cological cancer screening. Gynecologic examinations include uterine cytology (Papanicolaou 
test), transvaginal ultrasonography, and pelvic examination by a gynecologist.
Cervical and endometrial smears are performed using a speculum and/or brush. The cytol-
ogy findings divided into seven groups: high-grade squamous intraepithelial lesions (HSIL), 
low-grade squamous intraepithelial lesions (LSIL), atypical squamous cells of undetermined 
significance (ASC-US), squamous cell carcinoma, atypical glandular cells (AGC), cervical 
adenocarcinoma, and normal. The cytological findings of endometrium are classified into 
four categories: suspected endometrial carcinoma, atypical endometrial cell, benign endome-
trial abnormality, and normal endometrium. When inadequate for classification, smears were 
again taken from examinees, and their smear samples are retrospectively reviewed if needed.
Abnormal cytologic and/or ultrasonographic findings introduce all examinees to the medi-
cal facilities for further managements. Even though no additional information are provided 
regarding their detailed examination outcomes, the present findings obtained from asymp-
tomatic women may indicate annual gynecologic check-up and adequate follow-up programs 
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against symptom-free population, and this can cause remarkable reduction in the probability 
of malignant disease. The study sample is derived from the representative population of high-
income and high-attitude toward health maintenance, providing most of our observations as 
important implications in terms of public health.
If anything abnormal is found, the participants are provided the most appropriate advice, 
by determining whether follow-up observations would be sufficient, or if medical treatment 
is required, what kind of medical treatment should be provided, and what facility would be 
appropriate for a particular treatment.
3. Incidence of positive gynecological cancers in examinees of 
Ningen Dock
Table 2 shows the cytologic and ultrasonographic findings of all subjects who visited the Ningen 
Dock in our institute between 2002 and 2016 [3, 4]. Of the cytology from cervix, 140 cases (0.8%) 
Basic examination (1-day course)
Life Habits Check Investigation of lifestyle through medical questionnaire, 
physical check-up, and advice on how to prevent the 
development of diseases and how to treat them.
Lungs Chest X-ray to screening pulmonary disorders such as lung 
cancer, tuberculosis, and emphysema.
Heart Screening for high blood pressure and cardiac disorder by 
electrocardiogram.
Digestive organs Upper GI tests, abdominal ultrasonography, blood tests, 
and stool analysis to screen gastrointestinal diseases such as 
cancer, ulcer, polyp, and dysfunction of liver and pancreas by 
investigating esophagus, stomach, duodenum, liver, pancreas, 
and gallbladder.
Eyes Screening for cataract, glaucoma, and visual change by fundus 
photography and intraocular pressure measurement.
Breast X-ray and ultrasonography
Gynecology Screening for gynecological disorders such as uterine cancer 
and ovarian tumors through pelvic examination, cervical 
cytology and ultrasonography. Tumor markers (CA125, CA72-4, 
CA19-1, and SCC) are optional.
Others Screening tests for hearing, infections such as hepatitis virus 
and syphilis and determining blood type.
Optional
This course is arranged for those who want to take an opportunity to refresh and receive the screening in a more 
relaxed manner. The courses contain optional examinations that can be added upon the request.
Table 1. Test items of Ningen dock.
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were found as abnormal. Among them, 127 cases were classified as low-grade cervical smear 
abnormalities: LSIL and HSIL were seen in 105 cases, ASC-US was seen in 22. Suspected malig-
nancy of squamous cell was detected in five cases within this study period, while case of cervical 
adenocarcinoma was not found. No cytological abnormality categories were clustered in any 
specific age group. Endometrial smear showed hyperplasia suspicious in 2.7% cases.
Uterine enlargement was the most frequently detected gynecologic finding, with a peak 
reaching approximately 25% in 40–49 years age group. The uterine abnormalities had a ten-
dency to decrease in those aged over 60 years. Ovarian tumor (including solid and cystic 
enlargement) was detected in 5.2–8.0% of those in the age groups of 30–49 years, while those 
aged over 60 years had less frequency. In 91.3% participants, no gynecologic abnormality was 
detected.
The abnormal cytologic findings, including dysplastic changes and cervical cancer, are 
observed to be very low compared with other studies performed in developed countries 
(3.4–9%) [5–10]. Our findings based on 2011–2016 Ningen Dock records are similar to those of 
the former observations, and most of participants (95.6%) revealed no gynecological cytology 
Age group 
(years)
No. (%) Cytology Uterine 
tumor and 
abnormalities
Ovary 
tumor and 
abnormalities
Others*
Cervix EM
LSIL HSIL ASC-US SCC Other  
than 
normal
<19 12 (<0.1) 1 (<0.1) 0 0 0 0 0 2 (0.1) 0
20–29 794 (4.8) 9 (0.6) 0 5 (0.3) 1 (<0.1) 0 6 (0.4) 18 (1.3) 13 (0.9)
30–39 3172 
(19.2)
26 (1.8) 4 (0.3) 3 (0.2) 0 1 (<0.1) 80 (5.6) 74 (5.2) 68 (4.7)
40–49 6217 
(37.6)
37 (2.6) 6 (0.4) 3 (0.2) 1 (<0.1) 2 (0.1) 361 (25.2) 114 (8.0) 139 (9.7)
50–59 4615 
(27.9)
22 (1.5) 4 (0.3) 9 (0.6) 2 (0.1) 35 (2.4) 164 (11.4) 42 (2.9) 95 (6.6)
60–69 1464 
(8.9)
4 (0.3) 0 2 (0.1) 1 (<0.1) 0 44 (30.7) 8 (0.6) 16 (1.1)
70–79 228 (1.4) 0 0 0 0 0 5 (0.3) 1 (<0.1) 6 (0.4)
> 80 18 (<0.1) 0 0 0 0 0 0 0 0
Total 16,520 (100) 99 (0.6) 14 (<0.1) 22 (0.1) 5 (<0.1) 37 (0.2) 660 (4.0) 259 (1.6) 337 (2.0)
1433 (8.7)
Between January 2002 and December 2016, 16,520 asymptomatic women, aged 18–85, visited the Ningen Dock in 
Matsunami General Hospital for their gynecological health check-up. *Including vaginosis, leukoplakie, Bartholin cyst, 
posthysterectomy, cervical polyp, and prolaps/ptosis. LSIL, low-grade squamous intraepithelial lesion; HSIL, high-
grade squamous intraepithelial lesion; ASC-US, atypical squamous cells of undetermined significance; SCC, cervical 
squamous cell carcinoma; AGC, atypical glandular cells; EM; endometrium. Modified from our previous reports [3, 4].
Table 2. Gynecologic findings of participants distributed by age group.
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and ultrasonographic abnormalities. Gynecologic cancer is detected in 0.03%, all of which 
were at the early stages (so-called CIN3). The very low incident is in good agreement with 
the primary report in some Ningen Docks [1, 11].
HPV stands for human papilloma virus, which is a group of more than 200 viruses. Most 
people will get a HPV infection during their lifetime, usually from sexual activity. Most of 
these infections do not need treatment, but they can cause genital warts. In some, however, 
HPV infection causes changes in the cervix that can develop into cervical cancer. HPV can 
infect the cells on the surface of the cervix and damage them, causing their appearance to 
change and lead to abnormalities in these cells over a number of years. These abnormalities 
are known as cervical intraepithelial neoplasia (CIN). These changes are classified according 
to their severity. The mean time between the virus infection and invasive cancer takes about 
15 years, and within 2–4 years of detection 15.5–25.5% of low-grade epithelial lesions that 
become high-grade lesions. In some cases, these more severe changes can develop into cervi-
cal cancer. The progression of mild and severe changes to cancer takes many years so these 
abnormalities are known as precancerous [12–14]. HPV infection is most common in people in 
their late teens and early 20s [15, 16]. A study in Jordan, one of the most conservative and reli-
gious country, found that 0.8% of 1176 women aged 18–70 years are classified as ASC-US and 
0.2% as LSIL. In our unique system Ningen Dock in Japan, symptom-free women undergo 
medical check-up at their own expense. Their educational tradition and high concern on sex-
transmitted infection, such as HPV, may restrict the likelihood of multiple sexual partners. 
This may be the most plausible explanation for extremely low incidence of dysplastic changes 
and cervical cancer found in our study group of women.
As uterine enlargement, uterine myoma with or without adenomyosis are found in 20–25% 
of reproductive-age women, indicating that they are one of the most frequent women’s lower 
abdominal tumor [17–19]. The women with myoma do not necessarily complain of symp-
toms, and even large ones may go undetected by the patient, particularly if she is obese. 
Myoma-linked symptoms (abdominal distention, vaginal bleeding, constipation, and perito-
neal irritation) depend on their location, size, and state of presentation; symptoms are pres-
ent in 35–50% of patients with myomas. Ovarian tumors, cystic or solid, also seldom cause 
symptoms. Although the ovarian enlargement is frequently undetected by the patients, the 
diagnosis of these tumors is not usually difficult by ultrasonographic examination at physical 
check-up. Our subjects showed lower frequency of uterine enlargement and ovarian tumors.
Many previous trials demonstrated a reduction in the average overall mortality among ovar-
ian cancer patients screened with an annual sequential, multimodal strategy that tracked 
biomarkers CA125 over time, where increasing serum CA125 levels prompted ultrasound 
[20–23]. A critical factor which could contribute to false negatives is that many aggressive 
ovarian cancers are believed to arise from epithelial cells on the fimbriae of the fallopian tube, 
which are not readily imaged. In addition, because, only a fraction of metastatic tumors may 
reach an imaging device-detectable size before they metastasize, annual screening with imag-
ing diagnosis may fail to detect a large fraction of early stage ovarian cancers [24, 25]. The abil-
ity to detect ovarian carcinomas before they metastasize is critical and future efforts toward 
improving screening should focus on identifying unique features specific to aggressive, early 
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stage tumors, as well as improving imaging sensitivity to allow for detection of tubal lesions. 
So far, multimodal screening strategy in which blood-based assay is positive, and subsequent 
imaging examination may prove useful in detecting early stage cases [20–22, 25].
4. Gynecological cancer screening intervals
In many countries, undergoing cancer screening is not mandatory but voluntary. Many 
women are advised to annual gynecological screening for more than a decade. Recently, 
recommendations of many developed countries include one Pap smear every 3 years after 
two annual negative results from the age of 18 until 69 years [26]. According to the current 
American Cancer Society guidelines, adequate negative prior screening and no history of CIN 
2 of higher recommend that cervical smear test stops at age 65 [27]. On the other hand, annual 
screening continues among women of 65 years of age and older, even among those with less 
than a 5-year life expectancy due to poor health [28]. Likely, as clinical practice continues to 
change around the screening pelvic examination, consequent changes in utilization of repro-
ductive health services among young adolescence to postmenopausal.
First care visit volume is a key step for continuous use of an extended screening interval, with 
women who report to first gynecologic care visit during the last year being over 10 times more 
likely to report current use of a 3-year screening interval than those with three or more visits. It 
is not possible to separate which come first of less-frequent care seeking and an extended gyne-
cological cancers (including uterine and ovarian malignancies) screening interval. Clearly, some 
women are screened on 3-year intervals by default; however, others who purposefully follow 
an extended screening interval may have no perceived need to seek care during a given year.
The continuous screening preference of Japanese women may reflect long-held beliefs about 
the importance of annual cervical smear examinations and pelvic ultrasonographic examina-
tion with limited awareness of the potential harms associated with this practice. The level of 
knowledge and attitude toward screening are related to multiple factors such as ethnicity, 
place of residence, income, and social-economic status [29]. From an examiner perspective, 
annual gynecologic cancer screening has facilitated regular contact with examinees. In gen-
eral, women are invited by their gynecologists for the examination. The cytologic screening 
time interval depends on the doctor’s personal judgment [30]. If he feels that the test will ben-
efit their patients, the likelihood of performing the test increases. Some systemic review found 
a positive correlation of educational level, financial status, and an awareness of the mortality 
rates associated gynecological cancer with gynecological cancer attendance [26, 31, 32]. The 
level of knowledge and attitude toward health check-up are related to multiple factors such 
as ethnicity, place of residence, income, and social-economic status [33–37].
5. Discussion
Uterine cancer, in particular cervical cancer, is preventable. More than half of the women diag-
nosed with cervical cancer have not attended screening in the past 3 years. A community-based 
screening strategy is one of the greatest success stories in cancer prevention, and widespread 
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screening reduces the cervical cancer incidence worldwide [38–42]. The mean time between 
the virus infection and invasive cancer takes about 15 years, and within 2–4 years of detec-
tion 15.5–25.5% of low-grade epithelial lesions become high-grade lesions. In some cases, these 
more severe changes can develop into cervical cancer [5–10]. A routine screening test includes 
cytology smear test used for the detection of early cervical abnormalities (precancerous dys-
plastic changes) of the uterine cervix [5–10]. The screening is a relatively simple, low cost, and 
noninvasive method. Concurrent transvaginal ultrasonography for detection of ovarian and 
uterine tumors, the cervical and endometrial cytology smear tests attenuate the probability of 
developing gynecological malignant diseases.
Ningen Dock check-ups provide an occasion to realize preventive medicine. An important 
aim of gynecological health check-up is to provide support in improving the risk factors 
that accelerate the risk of outbreak of a malignant disease at an early stage, before subjective 
symptoms become apparent. Additionally, meticulous educational guidance is provided to 
match individual living patterns, education level, and ways of thinking. Ningen Dock can also 
conceive of time in the future when more appropriate and effective educational advice could 
be continuously provided according to a participant cultural background and lifestyle habits, 
via collaboration with health-related public services.
Qualitative evaluation of Ningen Dock Facilities consists of documentation and an inspection. 
These are administration of the facility, satisfaction and safety of examinees, and quality of 
check-up and follow-up [1]. Recently, the usefulness of Ningen Dock has greatly increased 
not only in the primary, but also in the secondary prevention of non-communicable diseases 
due to advances in diagnostic medical technology and therapeutic medicine. However, one 
of the problems is that relatively large numbers of Ningen Dock examinees who require a 
second, more detailed examination do not have the examination that has been recommended. 
For instance, only 61% of the Ningen Dock examinees who required total colon fiberscope as 
a second, detailed examination due to a positive fecal occult blood test underwent it. Similar 
tendencies were recognized for almost all Ningen Dock examinations [11]. The reason why 
Ningen Dock examinees who need second, more detailed examinations do not have them may 
be that most of them do not understand the importance of such examinations for the early 
detection of non-communicable diseases and their risk factors because we do not adequately 
explain the need for more detailed examinations to examinees. Therefore, better education of 
examinees may be urgently needed in order to further increase the usefulness of Ningen Dock.
In Japan, there are also free physical check-up programs of cancer screening, by which asymp-
tomatic participants undergo a medical examination at public expense. Takagi et al. [43] reported 
similar data using records of the public expense-covered free examination, and suggested that 
active gynecologic check-up and adequate follow-up programs even against symptom-free 
population can reduce in the probability of malignant disease development. Their findings 
from representative population of high-attitude toward screening, but non-high income, may 
give new insight into the terms of public health.
The present data are from subject to the limitations of any analysis of self-covered health 
check-up survey data from participants of Ningen Dock in Japan. Although data are weighted 
to reflect the Japanese population, the extent to which results are generalizable is no known. 
Future studies, extended to non-Asian, should attempt to oversample racial minorities and 
include a detailed assessment of gynecologic cancer screening history and follow-up treatment.
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Women attitudes and beliefs related to screening frequency may differ if they reflected 
truly informed preference and may be related to less screening. The present chapter intro-
duced the extremely low positive gynecology cancer screening incidence in Ningen Dock 
participants, providing the active strategy in the gynecological cancer screening practices 
of the lower screening attendance in Japan. However, strategies may be needed to encour-
age examiners to adopt recommended screening intervals and to educate women about the 
reasoning behind less-than-annual testing, including explicit discussions about the mean-
ingless and potential harms associated with excess screening.
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